BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 34868001)

  • 1. Kinase Inhibition as Treatment for Acute and Chronic Graft-
    Braun LM; Zeiser R
    Front Immunol; 2021; 12():760199. PubMed ID: 34868001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful management of acute graft-versus-host disease with ibrutinib during cord blood transplantation for germline
    Uchimura A; Yasuda H; Onagi H; Inano T; Shirane S; Ishii M; Azusawa Y; Hamano Y; Eguchi H; Arai M; Ando J; Ando M
    Heliyon; 2024 Jan; 10(2):e24801. PubMed ID: 38312561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect.
    Choi J; Cooper ML; Alahmari B; Ritchey J; Collins L; Holt M; DiPersio JF
    PLoS One; 2014; 9(10):e109799. PubMed ID: 25289677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) Differentiates GVL and GVHD in Allo-HSCT.
    Mammadli M; Huang W; Harris R; Sultana A; Cheng Y; Tong W; Pu J; Gentile T; Dsouza S; Yang Q; Bah A; August A; Karimi M
    Front Immunol; 2020; 11():593863. PubMed ID: 33324410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel JAK Inhibitors to Reduce Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation in a Preclinical Mouse Model.
    Kim S; Ruminski P; Singh M; Staser K; Ashami K; Ritchey J; Lim S; DiPersio JF; Choi J
    Molecules; 2024 Apr; 29(8):. PubMed ID: 38675621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease.
    Spoerl S; Mathew NR; Bscheider M; Schmitt-Graeff A; Chen S; Mueller T; Verbeek M; Fischer J; Otten V; Schmickl M; Maas-Bauer K; Finke J; Peschel C; Duyster J; Poeck H; Zeiser R; von Bubnoff N
    Blood; 2014 Jun; 123(24):3832-42. PubMed ID: 24711661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combinatorial inhibition of Tec kinases BTK and ITK is beneficial in ameliorating murine sclerodermatous chronic graft versus host disease.
    Palaniyandi S; Strattan E; Kumari R; Mysinger M; Hakim N; Kesler MV; Apatira M; Bittencourt F; Wang L; Jia Z; Gururaja TL; Hill RJ; Hildebrandt GC
    Bone Marrow Transplant; 2023 Aug; 58(8):924-935. PubMed ID: 37160943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic Inhibition of JAK1/JAK2 Signaling Reduces Experimental Murine Acute GVHD While Preserving GVT Effects.
    Carniti C; Gimondi S; Vendramin A; Recordati C; Confalonieri D; Bermema A; Corradini P; Mariotti J
    Clin Cancer Res; 2015 Aug; 21(16):3740-9. PubMed ID: 25977345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628).
    von Bubnoff N; Ihorst G; Grishina O; Röthling N; Bertz H; Duyster J; Finke J; Zeiser R
    BMC Cancer; 2018 Nov; 18(1):1132. PubMed ID: 30453910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Approaches for the Treatment of Chronic Graft-Versus-Host Disease: Current Status and Future Directions.
    Saidu NEB; Bonini C; Dickinson A; Grce M; Inngjerdingen M; Koehl U; Toubert A; Zeiser R; Galimberti S
    Front Immunol; 2020; 11():578314. PubMed ID: 33162993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
    Talmadge JE
    Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretransplant Short-Term Exposure of Donor Graft Cells to ITK Selective Inhibitor Ameliorates Acute Graft-versus-Host Disease by Inhibiting Effector T Cell Differentiation while Sparing Regulatory T Cells.
    Kondo T; Ikegawa S; Fukumi T; Sumii Y; Sugiura H; Sando Y; Nakamura M; Meguri Y; Iwamoto M; Maeda Y; Matsuoka KI
    Immunohorizons; 2021 Jun; 5(6):424-437. PubMed ID: 34112701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Janus kinase inhibition in the treatment and prevention of graft-versus-host disease.
    De Togni E; Cole O; Abboud R
    Front Immunol; 2024; 15():1304065. PubMed ID: 38380328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TAK1 inhibition ameliorates survival from graft-versus-host disease in an allogeneic murine marrow transplantation model.
    Kobayashi A; Kobayashi S; Miyai K; Osawa Y; Horiuchi T; Kato S; Maekawa T; Yamamura T; Watanabe J; Sato K; Tsuda H; Kimura F
    Int J Hematol; 2018 Feb; 107(2):222-229. PubMed ID: 29027124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration.
    Gao Y; Shan W; Gu T; Zhang J; Wu Y; Li X; Zeng X; Zhou H; Chen Z; Xiao H
    Front Immunol; 2021; 12():785774. PubMed ID: 34987512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease.
    Chang YJ; Zhao XY; Huang XJ
    Front Immunol; 2018; 9():3041. PubMed ID: 30619371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ruxolitinib in steroid refractory graft-vs.-host disease: a case report.
    Maffini E; Giaccone L; Festuccia M; Brunello L; Buondonno I; Ferrero D; Boccadoro M; Dellacasa C; Busca A; Novero D; Bruno B
    J Hematol Oncol; 2016 Aug; 9(1):67. PubMed ID: 27502249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic inhibition of PKCα and PKCθ prevents GVHD while preserving GVL activity in mice.
    Haarberg KM; Li J; Heinrichs J; Wang D; Liu C; Bronk CC; Kaosaard K; Owyang AM; Holland S; Masuda E; Tso K; Blazar BR; Anasetti C; Beg AA; Yu XZ
    Blood; 2013 Oct; 122(14):2500-11. PubMed ID: 23908466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunomodulatory Therapies for the Treatment of Graft-versus-host Disease.
    Braun LM; Zeiser R
    Hemasphere; 2021 Jun; 5(6):e581. PubMed ID: 34095764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.